Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).
Tetsuya Mitsudomi
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca; Sanofi
Expert Testimony - AstraZeneca (U)
Satoshi Morita
Honoraria - AstraZeneca
Yasushi Yatabe
No relevant relationships to disclose
Shunichi Negoro
Honoraria - AstraZeneca; Sanofi
Research Funding - AstraZeneca
Isamu Okamoto
No relevant relationships to disclose
Takashi Seto
Honoraria - AstraZeneca; Sanofi
Research Funding - AstraZeneca
Miyako Satouchi
Honoraria - AstraZeneca; Sanofi
Hirohito Tada
Honoraria - Sanofi
Tomonori Hirashima
No relevant relationships to disclose
Kazuhiro Asami
No relevant relationships to disclose
Nobuyuki Katakami
Honoraria - AstraZeneca; Bristol-Myers Squibb; Sanofi
Research Funding - AstraZeneca; Bristol-Myers Squibb; Sanofi
Minoru Takada
No relevant relationships to disclose
Hiroshige Yoshioka
Honoraria - AstraZeneca; Sanofi
Kazuhiko Shibata
Honoraria - AstraZeneca
Shinzoh Kudoh
No relevant relationships to disclose
Eiji Shimizu
No relevant relationships to disclose
Hiroshi Saito
Honoraria - AstraZeneca; Sanofi
Shinichi Toyooka
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Kazuhiko Nakagawa
Honoraria - AstraZeneca; Bristol-Myers Squibb; Sanofi
Masahiro Fukuoka
Honoraria - AstraZeneca